Paroxysmal Nocturnal Hemoglobinuria Market Expected to Surpass USD 1.5 Billion Across the 7MM Through 2036 as Next-Generation Complement Inhibitors Transform Treatment Landscape

According to DelveInsight's latest analysis, the Paroxysmal Nocturnal Hemoglobinuria (PNH) Market is poised for steady growth through 2036, driven by increasing disease awareness, improved diagnostic capabilities, expanding use of targeted complement inhibitors, and a strong late-stage pipeline of innovative therapies.
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare, acquired hematologic disorder characterized by chronic intravascular hemolysis, bone marrow failure, and life-threatening thromboembolic complications. Although considered an ultra-rare disease, significant advances in complement biology and targeted therapeutics have transformed the treatment landscape over the past decade. Today, continued innovation in complement inhibition, expanding access to precision diagnostics, and the emergence of novel pathway inhibitors are creating substantial opportunities for pharmaceutical companies and improving long-term outcomes for patients worldwide.
DelveInsight's latest report, "Paroxysmal Nocturnal Hemoglobinuria Market Insights, Epidemiology, and Market Forecast - 2036," offers a comprehensive assessment of the disease burden, epidemiology, current treatment landscape, marketed products, emerging therapies, competitive dynamics, and commercial opportunities across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

👉 Explore comprehensive market forecasts, epidemiology trends, competitive intelligence, and pipeline analysis in DelveInsight's latest Paroxysmal Nocturnal Hemoglobinuria Market report: https://www.delveinsight.com/report-store/paroxysmal-nocturnal-hemoglobinuria-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Key Highlights from the Paroxysmal Nocturnal Hemoglobinuria Market Report
• The PNH market across the 7MM exceeded USD 1.5 billion in 2025 and is projected to expand steadily through 2036.
• The market is anticipated to grow at a CAGR of 7.1% during 2026-2036.
• The United States accounted for nearly USD 950 million of the total market in 2025, making it the largest regional market.
• Approximately 6,200 diagnosed prevalent PNH cases were reported in the United States in 2025.
• Flow cytometry has become the gold standard for PNH diagnosis, replacing older Ham and sucrose tests.
• Approved complement inhibitors including SOLIRIS, ULTOMIRIS, EMPAVELI, and FABHALTA continue to dominate treatment.
• Several late-stage pipeline therapies, including Pozelimab + Cemdisiran and Zaltenibart (OMS906), are expected to strengthen future competition.

👉 Request a complimentary sample report to access detailed market forecasts, epidemiology insights, competitive intelligence, and emerging commercial opportunities: https://www.delveinsight.com/report-store/paroxysmal-nocturnal-hemoglobinuria-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Growing Awareness and Precision Diagnostics Continue to Expand the Market
Paroxysmal Nocturnal Hemoglobinuria develops due to acquired mutations in the PIG-A gene, resulting in the absence of glycosylphosphatidylinositol (GPI)-anchored proteins that normally protect blood cells from complement-mediated destruction. The disease manifests with chronic hemolysis, fatigue, anemia, thrombosis, and bone marrow dysfunction, creating a substantial clinical burden for affected patients.
The increasing adoption of flow cytometry (FCM) and FLAER-based diagnostic assays has significantly improved diagnostic accuracy, enabling earlier detection and more timely initiation of treatment. Growing physician awareness, expanding rare disease screening programs, and improved access to specialized hematology centers continue to increase diagnosis rates across major healthcare markets.
As healthcare systems increasingly prioritize early intervention and personalized medicine, the diagnosed patient pool is expected to grow steadily throughout the forecast period.

Paroxysmal Nocturnal Hemoglobinuria Recent Developments
The competitive landscape continues to evolve rapidly as pharmaceutical companies invest heavily in next-generation complement inhibitors.
• March 2025: Omeros Corporation announced activation of Phase III clinical trial sites evaluating Zaltenibart (OMS906) in patients with PNH.
• August 2024: Roche received European Commission approval for PIASKY for adults and adolescents with PNH.
• August 2024: The UK's MHRA approved FABHALTA (iptacopan) for the treatment of Paroxysmal Nocturnal Hemoglobinuria.
• December 2025: Novo Nordisk completed its acquisition and licensing agreement for Zaltenibart (OMS906), further strengthening its rare hematology portfolio.

👉 Stay updated on the latest clinical milestones, regulatory approvals, and commercial developments shaping the global PNH therapeutics market: https://www.delveinsight.com/report-store/paroxysmal-nocturnal-hemoglobinuria-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Paroxysmal Nocturnal Hemoglobinuria Current Treatment Landscape
The introduction of complement inhibitors has fundamentally changed the management of Paroxysmal Nocturnal Hemoglobinuria. Prior to the approval of targeted therapies, treatment options were largely supportive and focused on transfusions, anticoagulation, and symptom management.
Today, disease-modifying complement inhibitors have become the standard of care.

Current FDA-approved therapies include:
• SOLIRIS (eculizumab)
• ULTOMIRIS (ravulizumab)
• EMPAVELI/ASPAVELI (pegcetacoplan)
• FABHALTA (iptacopan)
These therapies significantly reduce intravascular hemolysis, lower transfusion requirements, decrease thrombotic events, and improve overall survival. Long-acting complement inhibitors have also reduced treatment burden by extending dosing intervals while maintaining sustained disease control.
Despite these advances, unmet needs remain. Some patients continue to experience extravascular hemolysis, breakthrough hemolysis, infection risks associated with terminal complement inhibition, and limited treatment options during pregnancy, highlighting the need for next-generation therapies.

Paroxysmal Nocturnal Hemoglobinuria Emerging Pipeline Strengthens Future Commercial Opportunities
Innovation within the PNH pipeline remains exceptionally strong, with multiple pharmaceutical companies developing therapies targeting different components of the complement cascade.

Among the most advanced pipeline candidates:
• Zaltenibart (OMS906) - Novo Nordisk
• Pozelimab + Cemdisiran - Regeneron Pharmaceuticals
• Additional proximal complement inhibitors targeting MASP-3, Factor B, and Factor D pathways

Unlike traditional C5 inhibitors, several investigational therapies are designed to provide broader complement control while potentially reducing residual hemolysis and improving long-term clinical outcomes.
These pipeline candidates have the potential to reshape future treatment algorithms and significantly expand the commercial landscape over the coming decade.

👉 Explore comprehensive pipeline intelligence, clinical trial analysis, launch timelines, and competitive benchmarking in DelveInsight's complete PNH Market Forecast Report: https://www.delveinsight.com/report-store/paroxysmal-nocturnal-hemoglobinuria-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Paroxysmal Nocturnal Hemoglobinuria Competitive Landscape
The Paroxysmal Nocturnal Hemoglobinuria market remains highly competitive as established pharmaceutical companies and emerging biotechnology firms continue investing in innovative complement-based therapies.

Leading companies include:
• Alexion Pharmaceuticals (AstraZeneca)
• Apellis Pharmaceuticals
• Novartis
• Novo Nordisk
• Regeneron Pharmaceuticals

Strategic acquisitions, licensing agreements, orphan drug incentives, and accelerated regulatory pathways continue to encourage innovation, while increasing competition is expected to expand treatment options and improve patient access worldwide.
Paroxysmal Nocturnal Hemoglobinuria Market Outlook Through 2036
According to DelveInsight, the Paroxysmal Nocturnal Hemoglobinuria market is expected to maintain strong growth through 2036. Rising disease awareness, broader adoption of advanced diagnostic techniques, expanding access to biologics, and continued investment in complement biology are expected to remain the primary market drivers.
The emergence of oral therapies, proximal complement inhibitors, and novel pathway-targeted treatments is expected to further improve convenience, efficacy, and patient quality of life. As pharmaceutical companies continue to invest in differentiated therapies capable of overcoming limitations associated with current C5 inhibitors, the competitive landscape will become increasingly dynamic.
The United States is expected to remain the largest market throughout the forecast period, while Europe and Japan are anticipated to experience steady expansion supported by favorable reimbursement policies, increasing diagnosis rates, and continued regulatory approvals.

👉 Read DelveInsight's complete Paroxysmal Nocturnal Hemoglobinuria Market Forecast - 2036 to explore market size, epidemiology, treatment trends, competitive intelligence, pipeline developments, and future commercial opportunities: https://www.delveinsight.com/report-store/paroxysmal-nocturnal-hemoglobinuria-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading healthcare market research and consulting firm specializing in life sciences and pharmaceuticals. The company delivers comprehensive market intelligence, epidemiology forecasts, competitive benchmarking, pipeline analysis, pricing and reimbursement assessments, and strategic consulting services to global pharmaceutical, biotechnology, and medical device companies. Through robust research methodologies and deep therapeutic expertise, DelveInsight empowers organizations to make informed business decisions and capitalize on emerging opportunities across the global healthcare landscape.

This release was published on openPR.